Clinical Trial Update: A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ibrutinib in combination with either bendamustine/rituximab or rituximab-based regimen in previously treated indolent non-Hodgkin lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2023-04-14